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Table
Relation of smoking status and intensity to widespread pain and knee pain severity.
Widespread pain at baseline Incident widespread pain at 84-month visit Knee pain severity (WOMAC) at baseline
N(%) of knees Adjusted OR* (95% CI) N(%) of knees Adjusted OR* (95% CI) N of knees Adjusted difference in
median* (95% CI)
Smoking status
never smoker 823/1655 (49.7) 1.0 (referent) 133/643 (20.7) 1.0 (referent) 1673 0 (referent)
current smoker 106/195 (54.4) 1.0 (0.7, 1.5) 12/53 (22.6) 0.9 (0.4, 2.0) 196 0.83 (0.03, 1.63)
former smoker 596/1147 (52.0) 1.3 (1.0, 1.5)1 92/400 (23.0) 1.2 (0.9, 1.7) 1154 0.00 (0.25, 0.25)
Smoking intensity (pack-year)
0 823/1655 (49.7) 1.0 (referent) 133/643 (20.7) 1.0 (referent) 1673 0 (referent)
1-10 251/495 (50.7) 1.2 (0.9, 1.5) 36/191 (18.8) 0.9 (0.6, 1.4) 497 0.33 (0.04, 0.70)
10-29 250/481 (52.0) 1.3 (1.0, 1.6)1 38/158 (24.1) 1.3 (0.8, 2.0) 484 0.17 (0.22, 0.56)
301 201/365 (55.1) 1.2 (0.9, 1.6) 30/103 (29.1) 1.7 (1.0, 2.8) 369 0.00 (0.43, 0.43)
*Adjusting for age. sex, race, clinic, BMI, Kellgren and Lawrence grade, CES-D score, and catastrophizing; p<0.0l
Abstracts / Osteoarthritis and Cartilage 23 (2015) A26eA81A62examined the cross-sectional association between smoking and WSP
at baseline using logistic regression, and between smoking and knee
pain severity at baseline using quantile regression with generalized
estimating equations to account for correlations between two knees
within a subject. We used the same approach to assess the effect of
baseline smoking on incident WSP. For pain sensitization outcomes,
we used logistic regression to assess the cross-sectional relation
between smoking and TS at 84-month visit, and used linear regres-
sion to assess the relation between smoking and PPT. Age, sex, race,
clinic, BMI, Kellgren and Lawrence grade of radiographic OA severity,
CES-D score, and catastrophizing were adjusted for as potential
confounders.
Results: Among 3026 subjects recruited at baseline (age mean ±; SD:
62.5 ±; 8.1, BMI mean ±; SD: 30.7 ±; 6.0 kg/m2, 60% women), 197
subjects (6.5%) were current smokers and 1155 (38.2%) were former
smokers. The median (25th, 75th percentile) smoking intensity among
smokers was 21.5 (15.0, 31.0) pack-years. The prevalence of WSP at
baseline were 50%, 55%, and 52% among never smokers, current
smokers and former smokers, with slightly higher prevalence among
former smokers compared with non-smokers (adjusted odds ratio
(95% CI) ¼ 1.3 (1.0, 1.5), p¼0.01). The risk of incident WSP at the 84-
month follow-up was similar among the three smoking status groups
(Table). While the prevalence of WSP at baseline did not differ by
smoking intensity, the risk of incident WSP increased with increasing
smoking intensity; smokers with 1-9, 10-29, 30 pack-years had odds
ratios of 0.9, 1.3 and 1.7, respectively, for risk of incident WSP com-
pared with non-smokers (p-value for linear trend ¼0.02). Knee pain
severity was higher among current smokers than non-smokers (Table),
but there was no relation to smoking intensity. The prevalence of TS at
84-month visit was 39%, and did not differ by smoking status or
intensity. Similarly, there was no difference in PPT by smoking status
or intensity.
Conclusions: Smoking intensity had a dose response relationship with
incident WSP, and current smoking was associated with knee pain
severity. No relation was observed between smoking and pain sensiti-
zation. The reasons for increased pain among smokers need further
clariﬁcation.
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TGF-b IS A POTENT INDUCER OF NERVE GROWTH FACTOR IN
ARTICULAR CARTILAGE VIA THE ALK5-SMAD2/3 PATHWAY.
POTENTIAL ROLE IN OA RELATED PAIN?
E. N. Blaney Davidson, A.P. van Caam, E.L. Vitters, M.B. Bennink,
E. Thijssen, W.B. van den Berg, M.I. Koenders, P.L. van Lent,
F.A. van de Loo, P.M. van der Kraan. Radboud Univ. Med. Ctr., Nijmegen,
Netherlands
Purpose: Pain is the main problem for patients with OA. Unfortunately,
pain relief is not effective in every individual. In general, pain is linked
to inﬂammation. However, in a subset of OA patients pain is experi-
enced without obvious inﬂammation driving the pain. This indicates
there must be an additional alternative source of pain besides inﬂam-
mation. NGF inhibition has been shown very efﬁcient in blocking pain
during OA, but the exact source of NGF is unclear. NGF is elevated in
human OA,as well as in animal models of OA with cartilage damage
without inﬂammation.TGF-beta is released from cartilage upondamage. We investigated whether TGF-beta could contribute to NGF
expression in the joint. Furthermore, we studied the speciﬁc Smad-
related TGF-beta pathways involved in this process.
Methods:Murine andhuman chondrocyte cell lines, primarybovine and
human chondrocytes, and cartilage explants from bovine metacarpal
joints and humanOA jointswere stimulatedwith TGF-b1 and/or IL-1b as
a positive control for NGF induction. We analyzed NGF expression on
mRNA level with QPCR and stained human OA cartilage for NGF immu-
nohistochemically. Cultures were additionally pre-incubated with
inhibitors for TAK1 (oxozeaenol), Smad2/3 (SB-505124) or Smad1/5/8
(LDN-193189) signaling to identify the TGF-b pathway inducing NGF.
Results: We found that TGF-beta was capable of inducing NGF
expression, even in low dosage of 1 ng/ml. NGF expression was con-
sistently induced at higher levels by TGF-b than IL-1 in all of our
experiments: murine, bovine and human origin, in cell lines, primary
chondrocytes and explants cultures. Combining TGF-beta with IL-1 did
not result in higher levels of NGF expression than those already reached
by a single dose of TGF-beta alone. As TAK1 is a common pathway
component of both IL-1 and TGF-beta signaling, we initially expected
TAK1 to be dominant and pivotal in NGF induction. TAK1 inhibition
consistently reduced (but not blocked) TGF-b-induced NGF whereas it
fully blocked IL-1b-induced NGF expression. In contrast, ALK5-Smad2/3
inhibition fully blocked TGF-b-induced NGF expression. Blocking the
Smad1/5/8 pathway with LDN did not have an effect on TGF-beta-
induced NGF. In human OA primary chondrocytes we found that there
was a large variation in basal NGF levels (mRNA and histology). Upon
stimulation with TGF-b we found a consistent higher level of NGF
induction than upon stimulationwith IL-1, which was not related to the
basal levels of NGF. In explants of human OA cartilage we observed
chondrocytes positive staining for NGF. When stimulating human OA
cartilage with TGF-beta NGF expression increased, which could be fully
blocked by inhibiting ALK5-Smad2/3 signaling.
Conclusions: This is the ﬁrst time that it is shown that TGF-b induces
NGF expression in (primary) chondrocytes. Moreover, we found that
TGF-beta consistently induced NGF at higher levels than IL-1. In addi-
tion, IL-1 induced NGF could be fully abrogated by TAK1 inhibition, but
this only had a reducing effect on TGF-beta induced NGF expression. In
contrast blocking signaling via ALK5-Smad2/3 fully abrogated the TGF-
beta-induced NGF expression. Clearly, our data show that there are
sources of NGF other than inﬂammation in the joint and that this should
be taken into account when studying pain in OA.
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CITED2 MEDIATES CROSS-TALK BETWEEN MECHANICAL LOADING
AND IL-4 AND RESULTS IN SYNERGISTIC CHONDROPROTECTION IN
VITRO AND IN VIVO
Z. He y, D.J. Leong y, L. Xu y, J.A. Hardin y, R.J. Majeska z, M.B. Schafﬂer z,
M.M. Thi y, L. Cardoso z, M.B. Goldring x, N.J. Cobelli y, H.B. Sun y. yAlbert
Einstein Coll. of Med., Bronx, NY, USA; z The City Coll. of New York, New
York, NY, USA; xHosp. for Special Surgery, New York, NY, USA
Purpose: Interleukin (IL)-4, is an anti-inﬂammatory cytokine that
reduces pro-inﬂammatory cytokine production and activity, and might
be chondroprotective. However clinical trials using IL-4 have not been
successful due to side effects from high doses of IL-4. CITED2 (CBP/
P300-interacting transactivator 2), originally identiﬁed as an IL-4-
